Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.64−0.02 (-3.31%)
Close on Nov 11, 2026Market cap $252.43MP/E 2.9Yield –
Standard BioTools enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Standard BioTools's enterprise value was -$224.59M on Nov 11, 2026, against $380.52M a year earlier. Over the last 5 years it ranged from -$237.53M to $479.82M, with a median of $107.11M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$224.59M | -175.8% |
| 2025 | Dec 31, 2025 | $296.12M | +4.3% |
| 2024 | Dec 31, 2024 | $283.84M | +517.3% |
| 2023 | Dec 29, 2023 | $45.98M | – |
| 2022 | Dec 30, 2022 | -$93.47M | -134.7% |
| 2021 | Dec 31, 2021 | $269.50M | -27.4% |
| 2020 | Dec 31, 2020 | $371.33M | +109.6% |
| 2019 | Dec 31, 2019 | $177.20M | -41.5% |
| 2018 | Dec 31, 2018 | $303.07M | +83.6% |
| 2017 | Dec 29, 2017 | $165.11M | +17.3% |
| 2016 | Dec 30, 2016 | $140.73M | -34.3% |
| 2015 | Dec 31, 2015 | $214.11M | -75.0% |
| 2014 | Dec 31, 2014 | $857.14M | -6.4% |
| 2013 | Dec 31, 2013 | $915.94M | +237.5% |
| 2012 | Dec 31, 2012 | $271.42M | +2.1% |
| 2011 | Dec 30, 2011 | $265.96M | – |
See a number that looks wrong?